Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03818087 · ClinicalTrials.gov registry record

Elevate! : An Elderly Breast Cancer Cohort Study

A clinical trial of Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
253
Enrollment target
4
Study locations

NCT03818087 is a study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 253 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03818087, a study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
253 participants
Enrollment target
4
Study locations

Study Summary

This study is focused on understanding how the investigators can improve upon breast cancer and health outcomes for older participants with breast cancer.

Conditions Studied

Interventions

  • BEHAVIORAL Observational cohort

Study Locations (4)

Massachusetts

  • Brigham and Women Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

Maine

  • Northern Light Cancer Care - Bangor

Rhode Island

  • Lifespan Cancer Institute - Providence

Trial Details

FieldValue
Enrollment Target 253 participants
Start Date 2019-02-19
Est. Completion 2028-11-01

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT03818087

The ClinicalTrials.gov registry entry for NCT03818087 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 253 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observational cohort is the first listed.

NCT03818087 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Massachusetts, Maine, Rhode Island.

Frequently Asked Questions

What is clinical trial NCT03818087 about?

NCT03818087 is a clinical study titled "Elevate! : An Elderly Breast Cancer Cohort Study". This study is focused on understanding how the investigators can improve upon breast cancer and health outcomes for older participants with breast cancer.

What is the current status of trial NCT03818087?

This trial is currently active not recruiting. The enrollment target is 253 participants. The study started on 2019-02-19. Estimated completion is 2028-11-01.

What conditions does trial NCT03818087 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT03818087?

The interventions under investigation include: Observational cohort (BEHAVIORAL).

Who is sponsoring clinical trial NCT03818087?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03818087 being conducted?

This trial has 4 study locations across Maine, Massachusetts, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.